|Bid||6.85 x 900|
|Ask||6.95 x 900|
|Day's Range||6.75 - 7.25|
|52 Week Range||6.75 - 36.65|
|Beta (3Y Monthly)||2.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.54|
The stocks’ response to a Washington Post article identifying a handful of companies as major makers or distributors of opioid drugs suggests investors haven’t fully priced in the potential damage from the continuing crisis.
STAINES-UPON-THAMES, United Kingdom and LONDON, July 18, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global biopharmaceutical company, and Silence Therapeutics plc (SLN.L), a leader in the discovery, development and delivery of novel RNA1 interference (RNAi) therapeutics for the treatment of serious diseases, announce that, further to the collaboration announced earlier today, Mallinckrodt, acting through a subsidiary company, has agreed to make an equity investment of $5 million in Silence Therapeutics. Mallinckrodt is subscribing for a total of 5,062,167 new ordinary shares at an issue price of 79p per share, representing a 10 percent premium to Silence's 20-day, volume-weighted average price. Application will be made to the London Stock Exchange for the admission of the 5,062,167 new ordinary shares to be subscribed for trading on AIM2. It is expected that dealings will commence at 8:00 a.m. BST3 on 24 July 2019. Immediately following admission, Mallinckrodt's shareholding will represent 6.5 percent of Silence Therapeutics' enlarged, issued share capital which will be 77,285,652 ordinary shares.
STAINES-UPON-THAMES, United Kingdom and LONDON, July 18, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global biopharmaceutical company, and Silence Therapeutics plc (SLN.L), a leader in the discovery, development and delivery of novel RNA2 interference (RNAi) therapeutics for the treatment of serious diseases, today announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation.
NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mallinckrodt plc (“Mallinckrodt” or the Company”) (NYSE: MNK) ...
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
STAINES-UPON-THAMES, United Kingdom, July 16, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty biopharmaceutical company, today announced that it is permanently discontinuing its Phase 2B study designed to assess the efficacy and safety of Acthar® Gel (repository corticotropin injection) as an investigational treatment for amyotrophic lateral sclerosis (ALS). Please see Important Safety Information for Acthar Gel below. Mallinckrodt made the decision to halt the trial after careful consideration of a recent recommendation by the study's independent Data and Safety Monitoring Board (DSMB).
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stocks have done so well nationally this year that the relatively few St. Louis companies have had a hard time keeping pace.
Callers will need to provide the Conference ID of 1778267. Through an audio replay: A replay of the call will be available beginning at 11:30 a.m. Eastern Time on Tuesday, Aug. 6, 2019, and ending at 11:59 p.m. Eastern Time on Tuesday, Aug. 20, 2019. All callers will be required to provide the Conference ID of 1778267.
Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.
STAINES-UPON-THAMES, United Kingdom, June 24, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty biopharmaceutical company, today confirmed it has achieved 50 percent patient enrollment in the company's Phase 2B study designed to assess the efficacy and safety of Acthar® Gel (repository corticotropin injection) as an investigational treatment for amyotrophic lateral sclerosis (ALS). The U.S. Food and Drug Administration (FDA) previously granted the company's request for a Fast Track designation and orphan status for its Acthar Gel Investigational New Drug application in patients with ALS. Please see Important Safety Information for Acthar Gel below.
The federal government has secured almost $850 million in settlements from the pharmaceutical industry since a Barron’s investigation revealed how companies used charities in ways that undermined efforts to hold back skyrocketing drug prices.
-- Study met primary outcome measure; 63 percent of patients with persistently active RA achieved low disease activity (LDA) as assessed by DAS28-ESR ¹ at Week 12 -- -- Randomized, placebo-controlled, ...
STAINES-UPON-THAMES, United Kingdom , June 11, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 25, 2019 , at the BMO Capital ...
Mallinckrodt Plc NYSE:MNKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MNK with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MNK totaled $9.22 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Justice Department accused Questcor in the years 2010-2014 of using a patient charity as a means of improperly subsidizing Medicare copayments in order to continue raising prices of H.P. Acthar gel, according to Reuters.
Shares of Mallinckrodt PLC dropped 2.4% in afternoon trade Wednesday, after the biopharmaceutical company said it reached an agreement in principle with the U.D. Department of Justice to resolve the investigation into the legacy sales and marketing activities of Questcor, which Mallinckrodt acquired in August 2014. Mallinckrodt expects to pay $15.4 million in the settlement, which will not contain any admission of wrongdoing. Meanwhile, the company intends to "vigorously defend" itself against any wrongdoing, with respect to the DOJ's newly filed allegations that Questcor's charitable activities between 2010 and 2014 violated the False Claims Act and the Anti-Kickback Statute. The stock has tumbled 58% over the past three months, while the S&P 500 has gained 1.1%.
STAINES-UPON-THAMES, United Kingdom, June 5, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global specialty biopharmaceutical company, today reported the company has reached an agreement in principle with the U.S. Department of Justice (DOJ) to resolve the previously disclosed government investigation of Questcor's legacy sales and marketing activities, which is still subject to the finalization of certain terms. Under the civil False Claims Act settlement, Mallinckrodt expects to pay $15.4 million relating to legacy Questcor activities.
BERWYN, Pa. , May 31, 2019 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Mallinckrodt plc (" Mallinckrodt ...